Abstract:Neurodegenerative diseases such as Alzheimer's disease and polyglutamine diseases are characterized by abnormal accumulation of misfolded proteins, leading to neuronal dysfunction and subsequent neuron death. However, there is a lack of studies that integrate molecular, morphological, and functional analyses in neurodegenerative models to fully characterize these time-dependent processes. In this study, we used C. elegans models expressing Aβ1-42 and polyglutamine to investigate early neuronal pathogenic features in olfactory neurons. Both models demonstrated significant reductions in odor sensitivity in AWB and AWC chemosensory neurons as early as day 1 of adulthood, while AWA chemosensory neurons showed no such decline, suggesting cell-type-specific early neuronal dysfunction. At the molecular level, Aβ1-42 or Q40 expression caused age-dependent protein aggregation and morphological changes in neurons. By day 6, both models displayed prominent protein aggregates in neuronal cell bodies and neurites. Notably, AWB neurons in both models showed significantly shortened cilia and increased instances of enlarged cilia as early as day 1 of adulthood. Furthermore, AWC neurons expressing Aβ1-42 displayed calcium signaling defects, with significantly reduced responses to odor stimuli on day 1, further supporting early behavioral dysfunction. In contrast, AWA neuron did not exhibit reduced calcium responses, consistent with the absence of detectable decreases in olfactory sensitivity in these neurons. These findings suggest that decreased calcium signaling and dysfunction in specific sensory neuron subtypes are early indicators of neurodegeneration in C. elegans , occurring prior to the formation of visible protein aggregates. We found that the ER unfolded protein response (UPR) is significantly activated in worms expressing Aβ1-42. Activation of the AMPK pathway alleviates olfactory defects and reduces fibrillar Aβ in these worms. This study underscores the use of C. elegans olfactory neurons as a model to elucidate mechanisms of proteostasis in neurodegenerative diseases and highlights the importance of integrated approaches.

Caenorhabditis Elegans As a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity.

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

A plant cell model of polyglutamine aggregation: Identification and characterisation of macromolecular and small-molecule anti-protein aggregation activity in vivo

The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans

Caenorhabditis Elegans As a Model System for Target Identification and Drug Screening Against Neurodegenerative Diseases.

Alleviating Neurodegeneration in Drosophila Models of PolyQ Diseases

Olfactory dysfunction as an early pathogenic indicator in C. elegans models of Alzheimer's and polyglutamine diseases

Modeling neurodegeneration in Caenorhabditis elegans

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity

3-Hydroxyanthranilic Acid Delays Paralysis in Caenorhabditis elegans Models of Amyloid-Beta and Polyglutamine Proteotoxicity

Genetic and Pharmacological Discovery for Alzheimer's Disease Using Caenorhabditis elegans.

Xyloketal-Derived Small Molecules Show Protective Effect by Decreasing Mutant Huntingtin Protein Aggregates in Caenorhabditis Elegans Model of Huntington'S Disease

Intracellular Degradation of Misfolded Proteins in Polyglutamine Neurodegenerative Diseases

Polyglutamine Length-Dependent Interaction of Hsp40 and Hsp70 Family Chaperones with Truncated N-terminal Huntingtin: Their Role in Suppression of Aggregation and Cellular Toxicity.

Large Animal Models of Huntington's Disease.

The protection of novel 2-arylethenylquinoline derivatives against impairment of associative learning memory induced by neural Aβ in C. elegans Alzheimer’s disease model

Endosome mediated nucleocytoplasmic trafficking and endomembrane allocation is crucial to polyglutamine toxicity

Disruption of the nascent polypeptide-associated complex leads to reduced polyglutamine aggregation and toxicity

Human Stem Cell Models of Polyglutamine Diseases: Sources for Disease Models and Cell Therapy

Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets